BAY94-9343
Sponsors
Bayer
Conditions
NeoplasmsOncology
Phase 1
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
CompletedNCT01439152
Start: 2011-09-07End: 2019-07-30Updated: 2021-07-09
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
CompletedNCT02485119
Start: 2015-08-14End: 2017-07-04Updated: 2018-06-04